Videos

Estay Greene, PharmD, MBA, offers key takeaways and provides closing thoughts on remaining unmet needs in the treatment of patients with diabetes.

Insights on how payers can allocate their resources to best improve outcomes for patients with diabetes.

Dr Brixner expands on evidence thresholds in the digital therapeutic space.

Diana Brixner, PhD, FAMCP, of the University of Utah opens a discussion surrounding digital therapeutics.

Payer perspectives on the challenges and advantages of integrating continuous glucose monitoring into diabetes management programs, highlighting the navigation of prior authorization requirements.

An expert on the treatment of diabetes offers insights on utilizing data to reveal disparities in care based on factors such as demographics and location.

Estay Greene, PharmD, MBA, outlines the main barriers that need to be addressed from a payer perspective in the treatment of high-risk patients with diabetes.

Mohannad Kusti, MD, examines opportunities to embrace recent innovations like telehealth consultations, remote monitoring, and clinical partnerships with top fertility clinics and research institutions to enable cutting-edge, personalized treatment plans.

Mohannad Kusti, MD, examines how comprehensive fertility benefits empower talent retention, yield a competitive edge, help prevent negative complications from improper fertility care, and mitigate costs from resulting absenteeism.

A medical expert discusses recent data and shared testimonials to educate employers on the value of fertility benefits, including contributions to diversity, equity, and inclusion.

Mohannad Kusti, MD, clarifies misconceptions around fertility benefits and their role in attracting, retaining, and empowering top talent.

Mohannad Kusti, MD, examines gaps in employer fertility coverage and reshaping employer perspective on fertility benefits.

Janet Choi, MD, gives closing thoughts on innovations in fertility benefits.

Janet Choi, M.D., spotlights the vital role of patient advocates in navigating fertility benefits and tackling care access gaps exacerbated by economic barriers, inadequate coverage and lack of emotional support throughout assisted reproductive treatment.

Janet Choi, M.D., examines enhancing the fertility patient experience and medical access from preconception through birth by reducing delays and barriers across the assisted reproductive treatment journey.

Expert, Janet Choi, M.D., advocates expanding financial coverage for inclusive fertility services to LGBTQ+ individuals and prospective single parents by choice seeking assistance to start families, countering disparities by making evidence-based treatments more accessible.

Janet Choi, M.D., discusses patient cost burden for fertility care and factors that may help reduce preterm births and miscarriages.

An expert examines the definition and benefits of fertility preservation options.

Janet Choi, MD, analyzes fertility care access, balancing the significant benefits of evidence-based reproductive treatment against the economic obstacles that restrict patient utilization of safe, effective interventions known to improve outcomes.

Sean Tipton underscores the importance of payer adoption of new treatments and technology which can lead to better patient outcomes.

An expert shares insight into expanding employer fertility coverage to maximize benefits and access to fertility care for employees.

Critical coverage considerations for SMA therapies are discussed.

Expert, Sean Tipton, discusses the current in vitro fertilization landscape and AI's potential to enhance fertility outcomes, pending sufficient payer coverage to drive clinical adoption.

An expert spotlights how open data communication between payers and fertility clinics can drive collaboration expanding coverage for proven, successful treatments that crucially improve assisted reproductive outcomes when timely access barriers are eliminated through aligned medical policies.

Important takeaways for patients, payers, and providers are covered by expert faculty.

Robert Spiera, M.D., highlights the significance of the SAPHYR trial, presenting a nonsteroid option for patients with refractory polymyalgia rheumatica that addresses unmet needs, reduces long-term corticosteroid-related burdens and benefits healthcare providers, payers, and patients alike.

Thomas Crawford, MD, discusses exciting new findings from the pivotal NURTURE study.

Robert Spiera, M.D., discusses the criteria for determining the suitability of sarilumab in polymyalgia rheumatica patients, with a particular focus on indicators of steroid intolerance.

In his final thoughts, Dr. Chervenak provides recommendations for optimal patient outcomes by tailoring design of health benefits.